Document Classification

Section Type: RESULTS

Text: The mean increase in number of migraine days was greater in the placebo group (1. 19 days in 4 weeks, 95 % CI 0. 71 to 1. 66 ; p < 0. 0001) than in the topiramate group (0. 10, -0. 36 to 0. 56 ; p = 0. 5756 ; mean difference between groups -1. 09, -1. 75 to -0. 43 ; p = 0. 0011) [corrected] Patients in the placebo group had a greater number of days on acute medication than did those in the topiramate group (mean difference between groups -0. 95, -1. 49 to -0. 41 ; p = 0. 0007).